a developer of immune based therapies for the treatment of brain and other cancers
Industry Biotechnology
A.I.dvisor tells us that IMUC and ANEB have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMUC and ANEB's prices will move in lockstep.
| Ticker / NAME | Correlation To IMUC | 1D Price Change % | ||
|---|---|---|---|---|
| IMUC | 100% | -0.06% | ||
| ANEB - IMUC | 23% Poorly correlated | +0.77% | ||
| VNDA - IMUC | 22% Poorly correlated | +2.16% | ||
| STTK - IMUC | 21% Poorly correlated | +5.50% | ||
| CCCC - IMUC | 21% Poorly correlated | -6.03% | ||
| BLUE - IMUC | 9% Poorly correlated | +14.85% | ||
More | ||||